GI/Hepatology Flashcards

1
Q

Initial treatment for type 1 autoimmune pancreatitis

A

High-dose PO prednisone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Treatment for severe alcoholic hepatitis, defined as Maddrey score > 32 or the presence of hepatic encephalopathy

A

Prednisolone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Appropriate colon cancer surveillance with colonoscopy for patients with 1 or 2 sessile serrated polyps < 10 mm without dysplasia

A

Every 5 to 10 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Diagnostic study for Budd-Chiari syndrome

A

US with doppler

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Post exposure prophylaxis for hepatitis A virus in nonimmune person

A

Hepatitis A virus vaccine

+ HAV immune globulin if > 40 y/o

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Diagnosis associated with insulinoma in patients <40 years old

A

MEN type 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Management for localized Ulcerative proctitis

A

Topical/suppository 5-ASA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Elevated serum ferritin level and transferring saturation

A

Hereditary hemochromatosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Study of choice for active lower GI bleeding with associated hemodynamic instability

A

CT angiography

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Treatment of choice for familiar adenomatous polyposis

A

Colectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Recommend surveillance for cervical cancer screening in patients with IBD receiving immuno suppressive therapy

A

Pap testing annually

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Dysphasia and food bolus obstruction usually found in younger men with a topic conditions

A

Eosinophilic esophagitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Recommend surveillance for patients with cirrhosis who have undergone virologic cure for Hepatitis C virus infection

A

US every 6 months for evaluation of HCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Recommended imaging modality for the diagnosis of acute mesenteric ischemia

A

CT angiography

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Equation for fecal osmotic gap

A

290 - (2 x [stool Na + stool K])

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Evaluation for suspected oropharyngeal dysphasia

A

Videofluoscopy with liquid and solid phases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Degeneration of the myenteric plexus with failure of the lower esophageal sphincter to relax in response to swallowing and absent peristalsis

A

Achalasia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Diagnostic evaluation for Achalasia in the following order

A

1) barium swallow
2) Esophageal manometry
3) Upper endoscopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

First line therapies for achalasia

A

Laparoscopic surgical myotomy of the LES and endoscopic pneumatic dilation of the esophagus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Appropriate evaluation for GERD refractory to empiric therapy with PPI

A

Upper endoscopy

If normal, ambulatory esophageal pH monitoring or impedance pH testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Surveillance for Barret esophagus and no dysplasia

A

Every 3 to 5 years

22
Q

Surveillance for Barret esophagus with low-grade dysplasia in those that do not choose endoscopic ablation

A

Every 6 to 12 months

23
Q

Evaluation for eosinophilic esophagitis

A

8 week trial of PPI

If symptoms refractory, this confirms diagnosis

If symptoms resolved, this indicates GERD-associate eosinophilia

24
Q

Timing of follow-up H. pylori testing After completion of therapy

A

4 weeks

25
Q

First line therapy for dumping syndrome

A

Smaller, more frequent meals

26
Q

Most common cause of recurrent celiac disease symptoms

A

Gluten exposure

27
Q

Management for esophageal hypomotility disorder

A

Lifestyle changes + PPI

28
Q

Painless obstructive jaundice with cross-sectional imaging revealing sausage-shaped pancreatic enlargement with and without elevated IgG4 levels

A

Type 1 Autoimmune pancreatitis (elevated IgG4)

Type 2 AIP (normal IgG4)

29
Q

1) Osmotic gap > 100 mOsm/kg H2O

2) Osmotic gap < 50 mOsm/kg H2O

A

1) osmotic diarrhea

2) secretory diarrhea

30
Q

Appropriate surveillance for patients with larger adenomas (>10 mm), 5-10 tubular adenomas <10 mm, Adenomas with tubulovillous histology, or other adenomas with high-grade dysplasia

A

Colonoscopy every 3 years

31
Q

Diagnosis of Puetz Jeghers syndrome requires 2 of the following 3 criteria:

A

1) >2 PJS-type hamartomatous polyps in the G.I. tract
2) Multiple melanogic macules in the mouth, bucc mucosa, nose, Eyes, fingers, genitalia
3) Family history of PJS

32
Q

Age at which patients with Lynch syndrome should be screened for colon and stomach/small bowel cancer

A

Colon: colonoscopy beginning at ages 20 to 25 years (or 2-5 years before the earliest cancer diagnosis in family)

Stomach/small bowel: Upper endoscopy beginning at age 30 to 35 years

33
Q

Surveillance for ulcerative pancolitis or Crohn disease

A

Colonoscopy beginning 8 years after diagnosis then performed every 1 to 2 years after

Proctocolectomy if dysplasia is found

34
Q

Poorly localized severe abdominal pain, often out of proportion to physical findings; peritoneal signs signify infarction

Diagnostic evaluation

Treatment

A

Acute mesenteric ischemia

CTA or selective mesenteric angiography

Peritoneal: urgent laparotomy
Not peritoneal: angiography

35
Q

Postprandial abdominal pain, Fear of eating, and weight loss; often signs and symptoms of atherosclerosis in other vascular beds

Diagnostic evaluation

Treatment

A

Chronic mesenteric ischemia

CTA, selective angiography, or MRA

Surgical reconstruction or angioplasty with stenting

36
Q

LLQ abdominal pain and self-limited bloody diarrhea

Diagnostic evaluation

Treatment

A

Ischemic colitis

Colonoscopy: patchy segmental ulcerations

Supportive care with IV fluids and bowel rest

37
Q

Management for gallbladder polyps > 1cm

A

Cholecystectomy

38
Q

Treatment for functional dyspepsia refractory to PPI

A

Tricyclic antidepressant

39
Q

Management for Canada esophagitis

A

PO fluconazole

40
Q

Appropriate management for dermatitis herpetiformis after resolution of celiac symptoms

A

Testing for G6PD deficiency prior to initiating dapsone

41
Q

Hepatitis A prophylaxis in

1) healthy persons <40 years old
2) Older adults and those who are immune compromised or half chronic liver disease

A

1) hepatitis A vaccine

2) Vaccine + immunoglobulin

42
Q

Hepatitis B prevention for postexposure prophylaxis after needlestick injury and for sexual and household contacts of patients with HBV

A

Hepatitis B vaccine + HBIG

43
Q

Recommended indications for treatment in patients with hepatitis B infection

A

1) acute liver failure or cirrhosis
2) Infection in the immune active phase
3) Infection in the reactivation phase (immune escape)
4) Immunosuppression or planned immunosuppression

44
Q

Treatment for hepatitis B virus

A

entecavir or tenofovir

45
Q

Indications for US Surveillance every 6 months in patients with HBC anD increased risk for HCC

A

1) cirrhosis
2) Asian men > 40 years and Asian women >50 years
3) Black patients > 20 years
4) Elevated ALT level and HBV DNA levels > 10,000 U/mL
5) Family history of HCC

46
Q

Initial diagnostic study for hepatitis C infection

A

Anti-HCV antibody

If positive, test for HCV RNA

47
Q

Patients with HCV who are candidates for liver transplantation

A

HCV + decompensated disease

Localized HCC

48
Q

HCC Ultrasound surveillance for patients with HCV cirrhosis

A

Every 6 months

49
Q

Indication for initiation and discontinuation of prednisolone in alcoholic hepatitis

A

Inititation: MDF > 32, MELD > 18, or encephalopathy and ascites

Discontinuation: If bilirubin level does not improve by day 7

50
Q

Most appropriate screening test for Hemochromatosis

A

Fasting serum transferrin saturation

51
Q

Diagnostic studies of Hemochromatosis

A

C282Y homozygous or C282Y/H63D compoubd heterozygous

52
Q

The diagnosis of Peutz-Jeghers syndrome is based on the presence of 2 of the following 3 criteria:

A

1) 2 or more PJS type hamartomatous polyps in G.I. tract
2) Multiple melanotic macules in the mouth, buccal mucosa, nose, eyes, genitalia, or fingers
3) Family history of PJS